News AZ sells US/Canada rights for old breast cancer drug AstraZeneca has sold US and Canadian rights to its older breast cancer drug Zoladex to TerSera Therapeutics in a deal worth up to $320 million.
Partner Content Partner Content Immuno-Oncology: A 360° View in NYC this February The Conference Forum has announced that the 3rd annual
News BMS and PsiOxus to collaborate on cancer-targeting armed vir... BMS to pay up to $936m for NG-348.
News AZ stakes its claim in immunotherapy with bladder cancer fil... After looking like it could get left far behind by rivals in immunotherapy, AstraZeneca has made its first filing for PD-L1 drug durvalumab .
News Avelumab filed, Pfizer and Merck prepare to join immunothera... Checkpoint inhibitor drug set to be fourth competitor in PD-1/PD-L1 market
News Scotland to fund BMS skin cancer combo Patient evidence convinces SMC Opdivo+Yervoy is cost-effective.
News Isomorphic adds MSD to partner roster, and other deals It's been a busy dealmaking week, with Isomorphic Labs, fresh from a $5 billion financing, adding MSD to its list of research alliances.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.